MA34836B1 - Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations - Google Patents

Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations

Info

Publication number
MA34836B1
MA34836B1 MA36127A MA36127A MA34836B1 MA 34836 B1 MA34836 B1 MA 34836B1 MA 36127 A MA36127 A MA 36127A MA 36127 A MA36127 A MA 36127A MA 34836 B1 MA34836 B1 MA 34836B1
Authority
MA
Morocco
Prior art keywords
condenses
substituted
heterocyclic compounds
nitrogenic
nitrogenic heterocyclic
Prior art date
Application number
MA36127A
Other languages
English (en)
Inventor
Lewis J Gazzard
Emily Hanan
Samuel Kintz
Joseph P Lyssikatos
Hans Edward Purkey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34836B1 publication Critical patent/MA34836B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

CETTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE FORMULE GÉNÉRALE (I) OÙ X1 EST N OU N+O-, ET UN DES X2, X3 ET X4 EST N OU N+-O-, LE RESTE DES X2, X3 ET X4 ÉTANT C. R2, R3, R4, R5, R6, A, B ET Y SONT TELS QUE DÉCRITS DANS LA PRÉSENTE. DE PLUS, DES COMPOSITIONS CONTENANT LES COMPOSÉS DE FORMULE (I) ET DES PROCÉDÉS POUR LES UTILISER SONT, EN OUTRE, DÉCRITS.
MA36127A 2010-12-17 2011-12-14 Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations MA34836B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424567P 2010-12-17 2010-12-17
PCT/EP2011/072666 WO2012080284A2 (fr) 2010-12-17 2011-12-14 Composés hétérocycliques azotés 6,6-condensés substitués et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34836B1 true MA34836B1 (fr) 2014-01-02

Family

ID=45418653

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36127A MA34836B1 (fr) 2010-12-17 2011-12-14 Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations

Country Status (18)

Country Link
US (3) US8623889B2 (fr)
EP (1) EP2651899B1 (fr)
JP (2) JP6026427B2 (fr)
KR (1) KR20130129244A (fr)
CN (1) CN103261167B (fr)
AR (1) AR084280A1 (fr)
AU (1) AU2011344270A1 (fr)
BR (1) BR112013013790A2 (fr)
CA (1) CA2817460A1 (fr)
CO (1) CO6741198A2 (fr)
CR (1) CR20130338A (fr)
EA (1) EA026115B1 (fr)
EC (1) ECSP13012771A (fr)
MA (1) MA34836B1 (fr)
MX (1) MX2013006101A (fr)
PH (1) PH12013501489A1 (fr)
TW (1) TW201307292A (fr)
WO (1) WO2012080284A2 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439014B2 (en) 2006-04-18 2008-10-21 Advanced Liquid Logic, Inc. Droplet-based surface modification and washing
US8809068B2 (en) 2006-04-18 2014-08-19 Advanced Liquid Logic, Inc. Manipulation of beads in droplets and methods for manipulating droplets
EP2588473A1 (fr) * 2010-06-30 2013-05-08 Amgen Inc. Composés hétérocycliques contenant de l'azote comme inhibiteurs de pi3k-delta
TW201307292A (zh) * 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
BR112015005562A2 (pt) * 2012-09-14 2017-08-08 Eternity Bioscience Inc compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
WO2014044846A1 (fr) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. Dérivés de 3-(aryl- ou hétéroaryl-amino)-7-(3,5-diméthoxyphényl)isoquinoline comme inhibiteurs de fgfr utiles pour le traitement de troubles prolifératifs ou de la dysplasie
WO2014087165A1 (fr) * 2012-12-06 2014-06-12 University Of Bath Inhibiteurs de tankyrase
EP3013825B1 (fr) * 2013-06-24 2019-08-07 Amgen Inc. Procédés pour préparer des (1,2,4)-triazolo(4,3-a)pyridines
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
EP3237397B1 (fr) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Composés isoindoline pour le traitement du vih
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2017205536A2 (fr) * 2016-05-24 2017-11-30 Genentech, Inc. Composés thérapeutiques et leurs utilisations
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
AU2017300123A1 (en) * 2016-07-20 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as PERK inhibitors
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
WO2018216705A1 (fr) * 2017-05-23 2018-11-29 国立大学法人京都大学 Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
ES2953025T3 (es) * 2017-10-02 2023-11-07 1St Biotherapeutics Inc Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos
WO2019079626A1 (fr) 2017-10-19 2019-04-25 Samumed, Llc 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN111868058B (zh) * 2018-05-25 2023-06-13 上海和誉生物医药科技有限公司 一种fgfr抑制剂、其制备方法和在药学上的应用
CN111936493B (zh) * 2018-06-19 2023-05-26 上海和誉生物医药科技有限公司 一种高选择性FGFRi抑制剂及其制备方法和应用
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
GB201901760D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
MX2021010122A (es) 2019-02-22 2021-09-23 1St Biotherapeutics Inc Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
US20220160902A1 (en) * 2019-03-07 2022-05-26 1ST Biotherapeutics, Inc. [18F]-Labeled Benzothiazole Derivative As PET Radiotracer
CN114269720B (zh) * 2019-07-25 2025-03-28 库拉德夫制药私人有限公司 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US11767321B2 (en) * 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CA3195193A1 (fr) * 2020-10-29 2022-05-05 Peter H. Fuller Amides isoquinoline lies a n en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations associees
EP4263541A1 (fr) * 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Nouveaux dérivés d'aryl-pyrido-pyrimidin-one
CN112898273B (zh) * 2021-03-30 2022-05-31 海南锦瑞制药有限公司 伏立康唑的合成方法及应用
US20250017914A1 (en) * 2021-09-10 2025-01-16 Black Diamond Therapeutics, Inc. 6-aza-quinoline derivatives and related uses
EP4408427A4 (fr) * 2021-10-01 2025-10-15 Merck Sharp & Dohme Llc Système et procédé de compensation d'irm statique et dynamique
CN114605267B (zh) * 2022-03-18 2024-02-23 北京格林凯默科技有限公司 2-溴-n,n-二甲基苯胺的制备方法
CN114573460B (zh) * 2022-03-18 2024-04-26 北京格林凯默科技有限公司 3-溴-n,n-二甲基苯胺的制备方法
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg
EP4601644A1 (fr) * 2022-10-14 2025-08-20 Black Diamond Therapeutics, Inc. Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine
WO2024097953A1 (fr) * 2022-11-04 2024-05-10 Enliven Inc. Composés de naphtyridine pour l'inhibition de kinases raf
WO2024098001A1 (fr) * 2022-11-04 2024-05-10 Enliven Inc. Composés de naphthyridone pour l'inhibition de raf kinases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535321A (en) 1967-12-01 1970-10-20 Smithkline Corp 2-carbalkoxyaminodihydroquinazolines
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3034001A1 (de) * 1980-09-10 1982-04-22 Hoechst Ag, 6000 Frankfurt Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006124944A1 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs de 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile de la tpl2 kinase et procedes de fabrication et d'utilisation de ceux-ci
EP1899322B1 (fr) 2005-06-28 2009-09-02 Sanofi-Aventis Derives d'isoquinoline utilises en tant qu'inhibiteurs de rhokinase
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CA2651072A1 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composes heterocycliques 2-amino-substitues a cycles fusionnes
KR20100044251A (ko) 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
GB0812969D0 (en) * 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010088177A1 (fr) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité d'akt
TW201307292A (zh) * 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途

Also Published As

Publication number Publication date
US9206175B2 (en) 2015-12-08
TW201307292A (zh) 2013-02-16
PH12013501489A1 (en) 2013-08-28
KR20130129244A (ko) 2013-11-27
WO2012080284A3 (fr) 2012-09-07
CA2817460A1 (fr) 2012-06-21
BR112013013790A2 (pt) 2016-09-13
AU2011344270A1 (en) 2013-07-18
ECSP13012771A (es) 2014-01-31
MX2013006101A (es) 2013-07-02
CN103261167B (zh) 2016-05-04
HK1187606A1 (zh) 2014-04-11
US8623889B2 (en) 2014-01-07
JP6026427B2 (ja) 2016-11-16
US20160060262A1 (en) 2016-03-03
AR084280A1 (es) 2013-05-02
EA201390877A1 (ru) 2013-12-30
JP2014502601A (ja) 2014-02-03
EP2651899A2 (fr) 2013-10-23
US20140088076A1 (en) 2014-03-27
JP2017031207A (ja) 2017-02-09
EA026115B1 (ru) 2017-03-31
EP2651899B1 (fr) 2017-05-31
WO2012080284A2 (fr) 2012-06-21
US20120322785A1 (en) 2012-12-20
CR20130338A (es) 2013-08-09
CO6741198A2 (es) 2013-08-30
CN103261167A (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
MA55131B1 (fr) Nouveaux composés hétérocycliques
MA33492B1 (fr) Inhibiteurs de bace
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA37756A1 (fr) Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA30057B1 (fr) Nucleosides antiviraux
MA32171B1 (fr) Compose heterocyclique
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
DE602006015658D1 (de) Entzündungshemmende arylnitrilverbindungen
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
PE20140189A1 (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
PH12013501489A1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
FR2911339B1 (fr) Derives du furazane, leur preparation et les compositions energetiques les renfermant
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
CY1110900T1 (el) Χημικες ενωσεις
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA34946B1 (fr) Nouvelles benzodioxolepipérazines
WO2009040314A3 (fr) Nouveaux dérivés de l'acétone substitués par un hétéroaryle, appropriés comme inhibiteurs de la phospholipase a2